MARKET

FOLD

FOLD

Amicus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.33
+0.28
+3.09%
After Hours: 9.27 -0.06 -0.64% 17:39 07/29 EDT
OPEN
9.05
PREV CLOSE
9.05
HIGH
9.36
LOW
8.94
VOLUME
4.53M
TURNOVER
--
52 WEEK HIGH
25.39
52 WEEK LOW
8.60
MARKET CAP
2.48B
P/E (TTM)
-9.5968
1D
5D
1M
3M
1Y
5Y
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 11h ago
Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2021.
GlobeNewswire · 2d ago
Amicus earns a new bull at BTIG on prospects of Pompe disease candidate
Hailshadow/iStock via Getty Images Citing expert opinion on the company’s experimental therapy for Pompe disease, BTIG has assumed a buy rating on Amicus Therapeutics ([[FOLD]] +0.3%). In February, the company
Seekingalpha · 07/19 14:29
Insider Trends: 90-Days of Insider Buying at Amicus Therapeutics Eased Back with Share Disposition
MT Newswires · 07/14 21:26
Here is What Hedge Funds Think About Amicus Therapeutics, Inc. (FOLD)
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2...
Insider Monkey · 07/06 14:06
Amicus Therapeutics Stock Gives Every Indication Of Being Possible Value Trap
GuruFocus News · 07/06 04:00
Amylyx Pharmaceuticals Strengthens Board of Directors with Appointment of Daphne Quimi, Chief Financial Officer of Amicus Therapeutics
Amylyx Pharmaceuticals, Inc. today announced the addition of Daphne Quimi to its Board of Directors. Ms. Quimi brings more than 25 years of executive experience in the pharmaceutical and biotechnology industries with expertise in global finance operations,...
Business Wire · 06/29 12:00
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
Benzinga · 06/23 16:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FOLD. Analyze the recent business situations of Amicus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FOLD stock price target is 16.38 with a high estimate of 29.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 362
Institutional Holdings: 323.33M
% Owned: 121.53%
Shares Outstanding: 266.06M
TypeInstitutionsShares
Increased
97
32.08M
New
50
12.03M
Decreased
76
29.71M
Sold Out
64
15.04M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Chief Executive Officer/Director
John Crowley
President/Chief Operating Officer/Director
Bradley Campbell
Chief Financial Officer
Daphne Quimi
Chief Accounting Officer/Vice President - Finance/Controller
Samantha Prout
Chief Scientific Officer
Hung Do
General Counsel/Secretary
Ellen Rosenberg
Other
David Clark
Lead Director/Independent Director
Michael Raab
Independent Director
Lynn Bleil
Independent Director
Robert Essner
Independent Director
Michael Kelly
Independent Director
Margaret Mcglynn
Independent Director
Eiry Roberts
Independent Director
Glenn Sblendorio
Independent Director
Craig Wheeler
Independent Director
Burke Whitman
No Data
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Webull offers kinds of Amicus Therapeutics, Inc. stock information, including NASDAQ:FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.